Vanguard (TRVI) amends 13G/A after Jan 12, 2026 realignment
Rhea-AI Filing Summary
Trevi Therapeutics Inc: An amended Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned and 0% of the class as of the filing. The filing explains an internal realignment at The Vanguard Group, Inc. on January 12, 2026 that led certain subsidiaries to report separately.
The filing is administrative: it lists Vanguard's address and states Vanguard and related investment vehicles have the right to receive dividends or proceeds where applicable, and certifies that no single other person holds more than 5% of the class. The form is signed on 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Administrative update showing no beneficial ownership reported by Vanguard for Trevi.
The amendment documents an internal reorganization at The Vanguard Group, Inc. on January 12, 2026, and states certain subsidiaries now report ownership separately. The schedule reports 0 shares and 0% beneficial ownership.
This is a disclosure and reporting change rather than an economic transaction. Cash‑flow treatment and any subsidiary holdings are not quantified in this excerpt; subsequent filings by specific Vanguard subsidiaries may show holdings if present.
FAQ
Does The Vanguard Group report any ownership in TRVI in this amendment?
Why does Vanguard say ownership is reported separately after January 12, 2026?
Who signed the Schedule 13G/A for Vanguard on TRVI and when?
Does this amendment indicate any Vanguard subsidiary holds more than 5% of Trevi?
Will this Schedule 13G/A cause immediate market transactions or company action?